Viridian Therapeutics, Inc.DE (VRDN) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026before open 35 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Tue, May 5, 2026before open 35 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Wed, Nov 5, 2025before open 36 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Tue, May 6, 2025before open 36 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress - $24.7 million in Lumvoa ™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 - - Elegrobart Biologics License Application (BLA) submission on track for Q1 2027 - - VRDN-008 phase 1 data disclosure on track for Q4 2026 - - VRDN-292, a potential best-in-class TSHR inhibitor, expected to initiate a phase 1 clinical trial in patients in Q4 2026 - - Cash, cash equivalents, and marketable securities of $955.2 million as of Se" exhibit
Q3 FY2026 "Viridian expects to submit a BLA to the U.S. FDA for elegrobart in TED in Q1 2027." exhibit
Q3 FY2026 "VRDN-292: IND on track to initiate a phase 1 clinical trial in patients in Q4 2026" exhibit
Q3 FY2026 "VRDN-292 IND on track to support phase 1 clinical trial initiation in Q4 2026, starting in patients with Graves’ disease." exhibit
Q3 FY2026 "FcRn update on track for Q4 2026: Viridian expects to announce VRDN-008 phase 1 healthy volunteer data and development plans for the FcRn portfolio in Q4 2026." exhibit
Q2 FY2026 "In parallel, we continue to advance our R&D pipeline toward a planned BLA submission for elegrobart in the first quarter of 2027, and are on track to deliver on clinical development milestones for our FcRn and TSHR programs in the second half of this year." exhibit
Q2 FY2026 "Viridian is on track to submit a Biologics License Application (BLA) to the FDA for elegrobart in Q1 2027." exhibit
Q2 FY2026 "Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026 and expects to develop this program in TED and Graves’ disease." exhibit
Q2 FY2026 "VRDN-008: phase 1 healthy volunteer data expected in 2H 2026" exhibit
Q2 FY2026 "Viridian anticipates sharing development plans for VRDN-006 in 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/VRDN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/VRDN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

VRDN earnings date badge

HTML

<a href="https://veritasdata.dev/company/VRDN/"><img src="https://veritasdata.dev/embed/VRDN.svg" alt="VRDN earnings date" width="240" height="56"></a>

Markdown

[![VRDN earnings date](https://veritasdata.dev/embed/VRDN.svg)](https://veritasdata.dev/company/VRDN/)

Script

<script async src="https://veritasdata.dev/embed/VRDN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/VRDN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.